New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.

Autor:	Dubois B; Department of Neurology, University Hospitals Leuven, Leuven, Belgium., Kobelt G; European Health Economics, Mulhouse, France., Berg J; Mapi Group, Stockholm, Sweden., Capsa D; Mapi Group, Stockholm, Sweden., Gannedahl M; Mapi Group, Stockholm, Sweden.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2017 Aug; Vol. 23 (2_suppl), pp. 29-40.
DOI:	10.1177/1352458517708100
Abstrakt:	Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 1856 patients (mean age: 54 years) participated in Belgium; 66% were below retirement age, and of these, 44% were employed. Employment was related to disease severity, and MS affected productivity at work in 85% of the patients. Overall, 95% and 72% of the patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.703 and €26,400 at Expanded Disability Status Scale (EDSS) 0-3, 0.478 and €45,300 at EDSS 4-6.5, and 0.193 and €62,000 at EDSS 7-9. The mean cost of a relapse was estimated to be €3000. Conclusion: This study provides current data on MS in Belgium that are important for development of health policies and for estimating the value of current and future treatments.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu